Anika Therapeutics Share Price (NASDAQ: ANIK)

$9.4

▲

0.17

(1.84%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Anika Therapeutics Stock chart to analyse performance

Anika Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$9.16
Today's High:$9.44
$9.40
2.61%
Downside
Day's Volatility :3.02%
Upside
0.42%
52 Weeks Low:$7.87
52 Weeks High:$26.48
$9.40
16.28%
Downside
52 Weeks Volatility :70.28%
Upside
64.5%

Anika Therapeutics Stock Returns

Period	Anika Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.55%	3.6%	0.0%
6 Months	-45.12%	-7.7%	0.0%
1 Year	-62.47%	-12.6%	0.0%
3 Years	-58.85%	10.2%	-4.1%

Anika Therapeutics Inc Key Stats

Check Anika Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$9.23
Open	$9.155
Today's High	$9.44
Today's Low	$9.155
Market Capitalization	$135.2M
Today's Volume	$194.6K
52 Week High	$26.48
52 Week Low	$7.8701
Revenue TTM	$114.5M
EBITDA	$-1.6M
Earnings Per Share (EPS)	$-0.9
Profit Margin	-52.93%
Quarterly Earnings Growth YOY	-0.5%
Return On Equity TTM	-7.23%

Stock Returns calculator for Anika Therapeutics Stock including INR - Dollar returns

The Anika Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Anika Therapeutics investment value today

Current value as on today

₹42,660

Returns

₹57,340

(-57.34%)

Returns from Anika Therapeutics Stock

₹62,624 (-62.62%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Anika Therapeutics Stock

22%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Anika Therapeutics Stock from India on INDmoney has increased by 22% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Anika Therapeutics Inc

Name
Holdings %
Name
Holdings %
Trigran Investments Inc
14.12%
BlackRock Inc
10.54%
Caligan Partners LP
9.95%
Vanguard Group Inc
5.41%
Dimensional Fund Advisors, Inc.
4.32%
Opaleye Management Inc
4.08%

Analyst Recommendation on Anika Therapeutics Stock

Rating

Trend

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Anika Therapeutics(by analysts ranked 0 to 5 stars)

Anika Therapeutics Share Price Target

What analysts predicted

Upside of 84.4%

Target:

$17.33

Current:

$9.40

Anika Therapeutics share price target is $17.33, a slight Upside of 84.4% compared to current price of $9.40 as per analysts' prediction.

Anika Therapeutics Stock Insights

Price Movement
In the last 6 months, ANIK stock has moved down by -45.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 26.16M → 28.21M (in $), with an average increase of 7.3% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -29.91M → -3.97M (in $), with an average increase of 136.1% per quarter
ANIK vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 73.2%
ANIK vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 33.4% return, outperforming this stock by 91.6%
Price to Sales
ForANIK every $1 of sales, investors are willing to pay $1.2, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Anika Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$114.6M	↑ 8.58%
Net Income	$27.2M	↑ 45.25%
Net Profit Margin	23.73%	↑ 5.99%

	FY20	Y/Y Change
Revenue	$130.5M	↑ 13.83%
Net Income	$-24.0M	↓ 188.19%
Net Profit Margin	-18.38%	↓ 42.11%

	FY21	Y/Y Change
Revenue	$147.8M	↑ 13.29%
Net Income	$4.1M	↓ 117.24%
Net Profit Margin	2.8%	↑ 21.18%

	FY22	Y/Y Change
Revenue	$156.2M	↑ 5.71%
Net Income	$-14.9M	↓ 459.43%
Net Profit Margin	-9.51%	↓ 12.31%

	FY23	Y/Y Change
Revenue	$166.7M	↑ 6.67%
Net Income	$-82.7M	↑ 456.34%
Net Profit Margin	-49.6%	↓ 40.09%

	FY24	Y/Y Change
Revenue	$119.9M	↓ 28.05%
Net Income	$-56.4M	↓ 31.79%
Net Profit Margin	-47.02%	↑ 2.58%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$40.5M	↓ 5.7%
Net Income	$-4.5M	↓ 92.83%
Net Profit Margin	-11.14%	↑ 135.47%

	Q2 FY24	Q/Q Change
Revenue	$41.9M	↑ 3.45%
Net Income	$-88.0K	↓ 98.05%
Net Profit Margin	-0.21%	↑ 10.93%

	Q3 FY24	Q/Q Change
Revenue	$38.8M	↓ 7.56%
Net Income	$-29.9M	↑ 33897.73%
Net Profit Margin	-77.2%	↓ 76.99%

	Q4 FY24	Q/Q Change
Revenue	$30.6M	↓ 21.03%
Net Income	$-21.9M	↓ 26.92%
Net Profit Margin	-71.45%	↑ 5.75%

	Q1 FY25	Q/Q Change
Revenue	$26.2M	↓ 14.49%
Net Income	$-4.9M	↓ 77.71%
Net Profit Margin	-18.62%	↑ 52.83%

	Q2 FY25	Q/Q Change
Revenue	$28.2M	↑ 7.84%
Net Income	$-4.0M	↓ 18.53%
Net Profit Margin	-14.07%	↑ 4.55%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$85.9M	↑ 15.6%

	FY20	Y/Y Change
Profit	$69.0M	↓ 19.61%

	FY21	Y/Y Change
Profit	$82.9M	↑ 20.16%

	FY22	Y/Y Change
Profit	$93.6M	↑ 12.82%

	FY23	Y/Y Change
Profit	$82.5M	↓ 11.8%

	FY24	Y/Y Change
Profit	$76.0M	↓ 7.92%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$24.6M	↓ 6.46%

	Q2 FY24	Q/Q Change
Profit	$27.4M	↑ 11.11%

	Q3 FY24	Q/Q Change
Profit	$1.4M	↓ 94.74%

	Q4 FY24	Q/Q Change
Profit	$22.6M	↑ 1467.01%

	Q1 FY25	Q/Q Change
Profit	$14.7M	↓ 34.94%

	Q2 FY25	Q/Q Change
Profit	$14.4M	↓ 2.17%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$37.0M	↑ 5.98%
Investing Cash Flow	$39.7M	↓ 178.98%
Financing Cash Flow	$-8.1M	↓ 71.83%

	FY20	Y/Y Change
Operating Cash Flow	$13.1M	↓ 64.69%
Investing Cash Flow	$-71.3M	↓ 279.55%
Financing Cash Flow	$-3.8M	↓ 53.65%

	FY21	Y/Y Change
Operating Cash Flow	$8.4M	↓ 35.73%
Investing Cash Flow	$-3.1M	↓ 95.62%
Financing Cash Flow	$-6.8M	↑ 79.62%

	FY22	Y/Y Change
Operating Cash Flow	$4.4M	↓ 47.49%
Investing Cash Flow	$-7.5M	↑ 140.09%
Financing Cash Flow	$-4.9M	↓ 28.43%

	FY23	Y/Y Change
Operating Cash Flow	$-1.8M	↓ 140.55%
Investing Cash Flow	$-5.4M	↓ 27.5%
Financing Cash Flow	$-6.3M	↑ 30.34%

	FY24	Y/Y Change
Operating Cash Flow	$5.4M	↓ 402.18%
Investing Cash Flow	$-8.3M	↑ 53.57%
Financing Cash Flow	$-12.7M	↑ 101.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-126.0K	↓ 103.46%
Investing Cash Flow	$-1.8M	↓ 1.74%
Financing Cash Flow	$-2.3M	↓ 764.62%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.1M	↑ 748.41%
Investing Cash Flow	$-3.4M	↑ 88.22%
Financing Cash Flow	$-1.1M	↓ 51.12%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$5.0M	↓ 569.22%
Investing Cash Flow	$-1.8M	↓ 46.64%
Financing Cash Flow	$-4.0M	↑ 259.23%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$1.6M	↓ 68.46%
Investing Cash Flow	$-1.3M	↓ 28.03%
Financing Cash Flow	$-5.4M	↑ 34.15%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-130.0K	↓ 108.22%
Investing Cash Flow	$1.7M	↓ 227.93%
Financing Cash Flow	$-5.4M	↑ 1.57%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-189.0K	↑ 45.38%
Investing Cash Flow	$-539.0K	↓ 132.24%
Financing Cash Flow	$179.0K	↓ 103.29%

Anika Therapeutics Technicals Summary

Sell

Neutral

Buy

Anika Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Anika Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Anika Therapeutics Inc	9.26%	-45.12%	-62.47%	-58.85%	-74.28%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Anika Therapeutics Inc	NA	NA	92.3	-0.14	-0.07	-0.02	NA	10.24
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Anika Therapeutics Inc	Buy	$135.2M	-74.28%	NA	-52.93%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Organization	Anika Therapeutics
Employees	288
CEO	Dr. Cheryl Renee Blanchard Ph.D.
Industry	Health Technology

Key Management of Anika Therapeutics Inc

Name	Title
Dr. Cheryl Renee Blanchard Ph.D.	President, CEO & Director
Mr. Stephen D. Griffin	Executive VP, CFO & COO
Mr. David Colleran J.D.	Executive VP, General Counsel & Corporate Secretary
Mr. Ian W. McLeod	VP & Chief Accounting Officer
Mr. Mark Namaroff	Vice President of Investor Relations, ESG & Corporate Communications
Mr. James Chase	Senior Vice President of International Sales & Marketing
Mr. Ben Joseph	Vice President of Commercial & Corporate Development
Ms. Lisa Funiciello	Vice President of Human Resources
Ms. Mira Leiwant	Senior Vice President of Regulatory, Quality & Clinical Affairs

Important FAQs about investing in ANIK Stock from India :

What is Anika Therapeutics share price today?

Anika Therapeutics share price today is $9.40 as on August 30, 2025 at 1:29 am IST at the close of the market. Anika Therapeutics share today touched a day high of $9.44 and a low of $9.16.

What is the 52 week high and 52 week low for Anika Therapeutics share?

Anika Therapeutics share touched a 52 week high of $26.48 and a 52 week low of $7.87. Anika Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $9.40, lower by 64.5% versus the 52 week high.

How to invest in Anika Therapeutics Stock (ANIK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Anika Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Anika Therapeutics Shares that will get you 0.1596 shares as per Anika Therapeutics share price of $9.40 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Anika Therapeutics Stock (ANIK) from India?

Indian investors can start investing in Anika Therapeutics (ANIK) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Anika Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Anika Therapeutics share’s latest price of $9.40 as on August 30, 2025 at 1:29 am IST, you will get 1.0638 shares of Anika Therapeutics. Learn more about fractional shares .

What are the returns that Anika Therapeutics has given to Indian investors in the last 5 years?

Anika Therapeutics stock has given -74.28% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?